Peanut allergy vaccine - Allertein Therapeutics

Drug Profile

Peanut allergy vaccine - Allertein Therapeutics

Alternative Names: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3 - Allertein Therapeutics; EMP-123

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Allertein Therapeutics
  • Developer Allertein Therapeutics; National Institute of Allergy and Infectious Diseases
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Peanut hypersensitivity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Peanut-hypersensitivity in USA (Rectal, Liquid)
  • 31 Oct 2009 Phase-I clinical trials in Peanut allergy in USA (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top